Slingshot members are tracking this event:

Baxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
BXLT Community voting in process

Additional Information

Additional Relevant Details
  • ADYNOVI is built on ADVATE [Antihemophilic Factor (Recombinant)], the world's most prescribed FVIII treatment with more than 12 years of patient experience worldwide
  • Currently marketed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], ADYNOVI is an innovative recombinant Factor VIII treatment designed to offer simple, twice-weekly dosing
  • Baxalta remains committed to bringing new innovative treatments to the hemophilia community, providing options for personalized care
  • http://newsroom.baxa...
    Slingshot Insights Explained
    Catalyst Date
    Occurred on:
    Mar 02, 2016
    Related Projects Image
    • Don’t see a project related to the catalyst you care about?

    Related Keywords Adynovi, Advate, Recombinant, Hemophilia, Pegylated, Hemophilia A